Assessment of congenital anomalies in infants born to pregnant women enrolled in clinical trials

Clinical Infectious Diseases

Volumn 59, Issue , 2014, Pages S428-S436

  Rasmussen, Sonja A ^a   Hernandez Diaz, Sonia ^b   Abdul Rahman, Omar A ^c   Sahin, Leyla ^d   Petrie, Carey R ^e   Keppler Noreuil, Kim M ^f   Frey, Sharon E ^g   Mason, Robin M ^f   Nesin, Mirjana ^f   Carey, John C ^h  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c UNIVERSITY OF MISSISSIPPI MEDICAL CENTER   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e EMMES CORPORATION   (United States)

^f NATIONAL INSTITUTES OF HEALTH   (United States)

^g SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Birth defects; Clinical trials; Congenital anomalies; Pregnant women

Indexed keywords

ANTICONVULSIVE AGENT; ANTIINFECTIVE AGENT; VACCINE;

ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL (TOPIC); CONGENITAL MALFORMATION; DISEASE SURVEILLANCE; FEMALE; HUMAN; INFANT; MEDICAL PHOTOGRAPHY; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; MEDICAL SPECIALIST; NON PROFIT ORGANIZATION; PHYSICAL EXAMINATION; PREGNANCY; PREGNANT WOMAN; PRIORITY JOURNAL; STANDARDIZATION; TERATOLOGY; CONGENITAL ABNORMALITIES; NEWBORN; UNITED STATES;

ANTI-INFECTIVE AGENTS; CLINICAL TRIALS AS TOPIC; CONGENITAL ABNORMALITIES; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; PREGNANCY; PREGNANT WOMEN; UNITED STATES; VACCINES;

EID: 84979854840     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu738     Document Type: Article

References (41)

1. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Medication use during pregnancy and lactation: an urgent call for public health action. JWomens Health (Larchmt) 2005; 14:104-9.
2. Shields KE, Lyerly AD. Exclusion of pregnant women from industrysponsored clinical trials. Obstet Gynecol 2013; 122:1077-81.
3. Blehar MC, Spong C, Grady C, Goldkind SF, Sahin L, Clayton JA. Enrolling pregnant women: issues in clinical research.Womens Health Issues 2013; 23:e39-45.
4. Munoz FM, Sheffield JS, Beigi RH, et al. Research on vaccines during pregnancy: Protocol design and assessment of safety. Vaccine 2013; 31:4274-9.
5. Sheffield JS, Munoz FM, Beigi RH, et al. Research on vaccines during pregnancy: reference values for vital signs and laboratory assessments. Vaccine 2013; 31:4264-73.
6. CDC. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morb Mortal Wkly Rep 2008; 57:1-5.
7. Biesecker LG, Aase JM, Clericuzio C, Gurrieri F, Temple IK, Toriello H. Elements of morphology: standard terminology for the hands and feet. Am J Med Genet A 2009; 149A:93-127.
8. Hall BD, Graham JM Jr., Cassidy SB, Opitz JM. Elements of morphology: standard terminology for the periorbital region. Am J Med Genet A 2009; 149A:29-39.
9. Leppig KA, Werler MM, Cann CI, Cook CA, Holmes LB. Predictive value of minor anomalies. I. Association with major malformations. J Pediatr 1987; 110:531-7.
10. Frias JL, Carey JC. Mild errors of morphogenesis. Adv Pediatr 1996; 43:27-75.
11. Preus M, Fraser FC. Dermatoglyphics and syndromes. Am J Dis Child 1972; 124:933-43.
12. Jones KL, Smith DW. Recognition of the fetal alcohol syndrome in early infancy. Lancet 1973; 302:999-1001.
13. Hanson JW, Myrianthopoulos NC, Harvey MA, Smith DW. Risks to the offspring of women treated with hydantoin anticonvulsants, with emphasis on the fetal hydantoin syndrome. J Pediatr 1976; 89:662-8.
14. Jones KL, Carey JC. The importance of dysmorphology in the identification of new human teratogens. Am J Med Genet C Semin Med Genet 2011; 157C:188-94.
15. Marden PM, Smith DW, McDonald MJ. Congenital anomalies in the newborn infant, including minor variations: a study of 4,412 babies by surface examination for anomalies and buccal smear for sex chromatin. J Pediatr 1964; 64:357-71.
16. Mehes K, Mestyan J, Knoch V, Vinceller M. Minor malformations in the neonate. Helv Paediatr Acta 1973; 28:477-83.
17. Merlob P, Papier CM, Klingberg MA, Reisner SH. Incidence of congenital malformations in the newborn, particularly minor abnormalities. Prog Clin Biol Res 1985; 163C:51-5.
18. Holmes LB, Kleiner BC, Leppig KA, Cann CI, Munoz A, Polk BF. Predictive value of minor anomalies: II. Use in cohort studies to identify teratogens. Teratology 1987; 36:291-7.
19. Cragan JD, Gilboa SM. Including prenatal diagnoses in birth defects monitoring: experience of the Metropolitan Atlanta Congenital Defects Program. Birth Defects Res A Clin Mol Teratol 2009; 85:20-9.
20. Bosi G, Garani G, Scorrano M, Calzolari E, Party IW. Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry. J Pediatr 2003; 142:690-8.
21. Minette MS, Sahn DJ. Ventricular septal defects. Circulation 2006; 114:2190-7.
22. Boulet SL, Shin M, Kirby RS, Goodman D, Correa A. Sensitivity of birth certificate reports of birth defects in Atlanta, 1995-2005: effects of maternal, infant, and hospital characteristics. Public Health Rep 2011; 126:186-94.
23. Rasmussen SA, Mulinare J, Khoury MJ, Maloney EK. Evaluation of birth defect histories obtained through maternal interviews. Am J Hum Genet 1990; 46:478-85.
24. Holmes LB, Baldwin EJ, Smith CR, et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy. Neurology 2008; 70:2152-8.
25. Holmes LB, Wyszynski DF, Lieberman E. The AED (antiepileptic drug) pregnancy registry: a 6-year experience. Arch Neurol 2004; 61:673-8.
26. Wyszynski DF, Nambisan M, Surve T, et al. Increased rate of major malformations in offspring exposed to valproate during pregnancy. Neurology 2005; 64:961-5.
27. Kennedy DL, Uhl K, Kweder SL. Pregnancy exposure registries. Drug Saf 2004; 27:215-28.
28. Holmes LB. Need for inclusion and exclusion criteria for the structural abnormalities recorded in children born from exposed pregnancies. Teratology 1999; 59:1-2.
29. Nelson K, Holmes LB. Malformations due to presumed spontaneous mutations in newborn infants. N Engl J Med 1989; 320:19-23.
30. Holmes LB, Westgate MN. Inclusion and exclusion criteria for malformations in newborn infants exposed to potential teratogens. Birth Defects Res A Clin Mol Teratol 2011; 91:807-12.
31. Peller AJ, Westgate MN, Holmes LB. Trends in congenital malformations, 1974-1999: effect of prenatal diagnosis and elective termination. Obstet Gynecol 2004; 104:957-64.
32. Guttmacher AE, Hirschfeld S, Collins FS. The National Children's Study-A proposed plan. N Engl J Med 2013; 369:1873-5.
33. Allanson JE, Biesecker LG, Carey JC, Hennekam RC. Elements of morphology: introduction. Am J Med Genet A 2009; 149A:2-5.
34. Abdul-Rahman OA, Hayes L, Loyola B, et al. Development of a Visit Assessment Tool to Address Birth Defects and Dysmorphology. In: Presented at the Annual Meeting of the David W. Smith Workshop on Malformations and Morphogenesis, August 9, 2012, Lake Lanier Islands, GA.
35. Chambers CD, Braddock SR, Briggs GG, et al. Postmarketing surveillance for human teratogenicity: a model approach. Teratology 2001; 64:252-61.
36. Miller MT, Stromland K. Teratogen update: thalidomide: a review, with a focus on ocular findings and new potential uses. Teratology 1999; 60:306-21.
37. Hyoun SC, Obican SG, Scialli AR. Teratogen update: methotrexate. Birth Defects Res A Clin Mol Teratol 2012; 94:187-207.
38. Douglas TS, Mutsvangwa TE. A review of facial image analysis for delineation of the facial phenotype associated with fetal alcohol syndrome. Am J Med Genet A 2010; 152A:528-36.
39. Singh S, Loke YK. Drug safety assessment in clinical trials: methodological challenges and opportunities. Trials 2012; 13:138.
40. Friedman JM. ABCDXXX: The obscenity of postmarketing surveillance for teratogenic effects. Birth Defects Res A Clin Mol Teratol 2012; 94:670-6.
41. Food and Drug Administration/Center for Drug Evaluation and Research and Center for Biologics Evaluation and Research. Guidance for Industry: Providing Regulatory Submissions in Electronic Format-Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/downloads/Drugs/Guidances/UCM384686.pdf Accessed 1 June 2014.